Two such strategies, low-dose interleukin-2 (IL-2) administration and Treg cell adoptive transfer, have received much attention in recent research and have been tested in clinical trials for several autoimmune diseases (40, 51, 52, 55, 79–82) (Table 1). This evidence concerns the gene IL2 and autoimmune disease.